Vitamin D Pilot Study in Patients With Multiple Sclerosis

This study has been completed.
Information provided by:
University of Wisconsin, Madison Identifier:
First received: December 8, 2010
Last updated: June 14, 2011
Last verified: December 2010

Phase 1 study of 19-nor Vitamin D in relapsing-remitting MS. Primary measure is MRI.

Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis
Drug: 19 nor vitamin d
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Vitamin D Pilot Study in Patients With Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • MRI Measure of new active lesions, observation vs. treatment

Study Start Date: February 1998
Study Completion Date: June 2000
Primary Completion Date: February 2000 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 19 nor vitamin d Drug: 19 nor vitamin d


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • relapsing remitting MS

Exclusion Criteria:

  • MRI contraindicated
  Contacts and Locations
Please refer to this study by its identifier: NCT01257958

United States, Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
  More Information

No publications provided

Responsible Party: John Fleming, MD, Department of Neurology - UW Madison Identifier: NCT01257958     History of Changes
Other Study ID Numbers: HSC #97-676-311
Study First Received: December 8, 2010
Last Updated: June 14, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Wisconsin, Madison:
Vitamin D, 19 nor Vitamin D, Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Vitamin D
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Growth Substances processed this record on April 17, 2014